Alyce S Adams1, Stephen B Soumerai2, Fang Zhang2, Daniel Gilden3, Marguerite Burns4, Haiden A Huskamp5, Connie Trinacty6, Margarita Alegria7, Robert F LeCates2, Jennifer J Griggs8, Dennis Ross-Degnan2, Jeanne M Madden2. 1. Division of Research, Kaiser Permanente, Oakland, California. Electronic address: Alyce.S.Adams@kp.org. 2. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts. 3. JEN Associates, Inc, Cambridge, Massachusetts. 4. Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin. 5. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts. 6. Center for Health Research, Kaiser Permanente, Honolulu, Hawaii. 7. Center for Multicultural Mental Health Research, Cambridge Health Alliance and Harvard Medical School, Somerville, Massachusetts. 8. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
PURPOSE: Black patients with diabetes are at greater risk of underuse of antidepressants even when they have equal access to health insurance. This study aimed to evaluate the impact of removing a significant financial barrier to prescription medications (drug caps) on existing black-white disparities in antidepressant treatment rates among patients with diabetes and comorbid depression. METHODS: We used an interrupted time series with comparison series design and a 5% representative sample of all fee-for-service Medicare and Medicaid dual enrollees to evaluate the removal of drug caps on monthly antidepressant treatment rates. We evaluated the impact of drug cap removal on racial gaps in treatment by modeling the month-to-month white-black difference in use within age strata (younger than 65 years of age or 65 years of age or older). We compared adult dual enrollees with diabetes and comorbid depression living in states with strict drug caps (n = 221) and those without drug caps (n = 1133) before the policy change. Our primary outcome measures were the proportion of patients with any antidepressant use per month and the mean standardized monthly doses (SMDs) of antidepressants per month. FINDINGS: The removal of drug caps in strict drug cap states was associated with a sudden increase in the proportion of patients treated for depression (4 percentage points; 95% CI, 0.03-0.05, P < 0.0001) and in the intensity of antidepressant use (SMD: 0.05; 95% CI, 0.03-0.07, P < 0.001). Although antidepressant treatment rates increased for both white and black patients, the white-black treatment gap increased immediately after Part D (0.04 percentage points; 95% CI, 0.01-0.08) and grew over time (0.04 percentage points per month; 95% CI, 0.002-0.01; P < 0.001). IMPLICATIONS: Policies that remove financial barriers to medications may increase depression treatment rates among patients with diabetes overall while exacerbating treatment disparities. Tailored outreach may be needed to address nonfinancial barriers to mental health services use among black patients with diabetes.
PURPOSE: Black patients with diabetes are at greater risk of underuse of antidepressants even when they have equal access to health insurance. This study aimed to evaluate the impact of removing a significant financial barrier to prescription medications (drug caps) on existing black-white disparities in antidepressant treatment rates among patients with diabetes and comorbid depression. METHODS: We used an interrupted time series with comparison series design and a 5% representative sample of all fee-for-service Medicare and Medicaid dual enrollees to evaluate the removal of drug caps on monthly antidepressant treatment rates. We evaluated the impact of drug cap removal on racial gaps in treatment by modeling the month-to-month white-black difference in use within age strata (younger than 65 years of age or 65 years of age or older). We compared adult dual enrollees with diabetes and comorbid depression living in states with strict drug caps (n = 221) and those without drug caps (n = 1133) before the policy change. Our primary outcome measures were the proportion of patients with any antidepressant use per month and the mean standardized monthly doses (SMDs) of antidepressants per month. FINDINGS: The removal of drug caps in strict drug cap states was associated with a sudden increase in the proportion of patients treated for depression (4 percentage points; 95% CI, 0.03-0.05, P < 0.0001) and in the intensity of antidepressant use (SMD: 0.05; 95% CI, 0.03-0.07, P < 0.001). Although antidepressant treatment rates increased for both white and black patients, the white-black treatment gap increased immediately after Part D (0.04 percentage points; 95% CI, 0.01-0.08) and grew over time (0.04 percentage points per month; 95% CI, 0.002-0.01; P < 0.001). IMPLICATIONS: Policies that remove financial barriers to medications may increase depression treatment rates among patients with diabetes overall while exacerbating treatment disparities. Tailored outreach may be needed to address nonfinancial barriers to mental health services use among black patients with diabetes.
Authors: Jeanne M Madden; Amy J Graves; Fang Zhang; Alyce S Adams; Becky A Briesacher; Dennis Ross-Degnan; Jerry H Gurwitz; Marsha Pierre-Jacques; Dana Gelb Safran; Gerald S Adler; Stephen B Soumerai Journal: JAMA Date: 2008-04-23 Impact factor: 56.272
Authors: Wayne J Katon; Carolyn Rutter; Greg Simon; Elizabeth H B Lin; Evette Ludman; Paul Ciechanowski; Leslie Kinder; Bessie Young; Michael Von Korff Journal: Diabetes Care Date: 2005-11 Impact factor: 19.112
Authors: William H Shrank; Amanda R Patrick; Alex Pedan; Jennifer M Polinski; Laleh Varasteh; Raisa Levin; Nan Liu; Sebastian Schneeweiss Journal: J Am Geriatr Soc Date: 2008-12 Impact factor: 5.562
Authors: Alyce S Adams; Jeanne M Madden; Fang Zhang; Christine Y Lu; Dennis Ross-Degnan; Angelina Lee; Stephen B Soumerai; Dan Gilden; Neetu Chawla; Jennifer J Griggs Journal: Value Health Date: 2017-07-06 Impact factor: 5.725
Authors: Natalie S Hohmann; Tessa J Hastings; Ruth N Jeminiwa; Jingjing Qian; Richard A Hansen; Surachat Ngorsuraches; Kimberly B Garza Journal: Res Social Adm Pharm Date: 2021-02-05
Authors: Laura-Louise Arundell; Helen Greenwood; Helen Baldwin; Eleanor Kotas; Shubulade Smith; Kasia Trojanowska; Chris Cooper Journal: Syst Rev Date: 2020-05-26